News und Analysen
Valbiotis: Exklusivvereinbarung mit ADECAL Technopole und IFREMER stärkt Entwicklung innovativer natürlicher Gesundheitslösungen durch die Integration der Erforschung von Mikroalgen aus Neukaledonien
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur
Valbiotis Consolidates Its Development of Innovative Natural Health Solutions by Integrating the Exploration of Microalgae Produced in New Caledonia, Through an Exclusive Agreement With ADECAL-Technopole and IFREMER
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a French research and development company committed to scientific innovation for preventing and combating of metabolic
Regulators Approve Sensorion’s Amendment to Phase 2 AUDIBLE-S Trial of SENS-401 in Sudden Sensorineural Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specialising in the development of novel therapies to restore, treat and prevent
Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial
Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the presentation of data
GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sensorion And Hearing Care Leader Sonova Sign Strategic Research Collaboration
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotech company specializing in the development of novel therapies to restore, treat, and prevent
Transgene Announces Upcoming Investor Meetings
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that Management will participate in
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital as of August 31, 2021
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris
Compartment: B
ISIN code: FR0011341205
Website: www.nanobiotix.com
Date
Number of Shares
Outstanding
Valbiotis Releases its Letter to Shareholders for 2021
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic
Valbiotis veröffentlicht Aktionärsbrief für 2021
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert) (Paris:ALVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher
THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION (BBDF) WIN US INVESTIGATIONAL NEW DRUG (IND) APPROVAL TO START CLINICAL DEVELOPMENT OF BBDF 101
Lyon, 9 September 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases, and Beyond Batten Disease Foundation (BBDF), announce receipt of
BOIRON : 2021 Half-Year Results
(Data have been the subject to a limited review by the statutory auditors)
The Board of Directors, at its meeting of September 8, 2021, made up the half-year statutory and consolidated financial
GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects Before LUMEVOQ® Treatment in Phase III Trials
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908006154/en/
Figure 1. BCVA in untreated ND4-LHON patients as a
NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021
Regulatory News:
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination With Cochlear Implantation
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology, which specializes in the development of novel therapies to restore, treat and prevent
Nanobiotix to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Valbiotis meldet Abschluss der Rekrutierung für klinische Phase-II-Studie HEART für TOTUM•070 bei Hypercholesterinämie, einem Risikofaktor für kardiovaskuläre Erkrankungen
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA/SME-fähig), ein französisches Forschungs- und Entwicklungsunternehmen, das sich wissenschaftlichen Innovationen zur Prävention und
Valbiotis Announces the Completion of Recruitment for the Phase II HEART Clinical Study Conducted With TOTUM•070 in Hypercholesterolemia, a Risk Factor for Cardiovascular Disease
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a French research and development company committed to scientific innovation for preventing and combating metabolic diseases
UK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Transgene Participates in New Cancer Research Consortium
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces its participation in the launch of
GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005575/en/
Figure 1. Evolution of best-corrected visual acuity
Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting
Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting
- Firibastat is as efficent as the current standard of care
2021 HALF-YEAR BOIRON ACTIVITY
Cumulative Activity as of the end of june 2021
In thousands of euros 2020 2021 Variation at current exchange rates Variation at constant exchange rates France 104,930 126,32Nanobiotix Provides Second Quarter Operational and Financial Update
Regulatory News:
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to